Rimonabant: SR 141716, SR 141716a

Drugs in R and D

Volumn 3, Issue 1, 2002, Pages 65-66

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; PLACEBO; RIMONABANT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRUCTURE ANALYSIS; TREATMENT INDICATION; WEIGHT REDUCTION; PSYCHOLOGICAL ASPECT; REVIEW;

ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION DISORDERS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 0036363804     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203010-00016     Document Type: Article

References (4)

1. Barth F, Rinaldi-Carmona M, Arnone M, Heshmati H, Le Fur G. Cannabinoid antagonists: from research tools to potential new drugs. 222nd American Chemical Society National Meeting - Part. 1. : abstr. MEDI 294, 26 Aug 2001. France. [English]
2. Terranova J-P, Storme J-J, Lafon N, et al.. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126: 165-172, Jul 1996. France. [English]
3. Coizet V, Cassel J-C, Kelche C. Effects of the selective CB1 cannabinoid receptor antagonist, SR 141716A, on cognitive performance in intact, brain-damaged and scopolamine-treated rats. Behavioural Pharmacology. 9 (Suppl 1): 25, Aug 1998. France. [English]
4. Heshmati HM, Caplain H, Bellisle F, et al.. SR141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake, and body weight in overweight or obese men. Obesity Research. 9 (Suppl 3): 70, Sep 2001. USA. [English]